GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
GeneType and Gold Coast Hospital Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital...
GeneType and Gold Coast Hospital Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital...
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and...
Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite...
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology HoldingsBiotechnology Veteran Bas van...
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE,...
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of...
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration...
Bionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for...
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with...
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers...
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6...
- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in...
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023...
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene...
71 Citation Laureates named by the Institute for Scientific Information have gone on to receive a Nobel Prize LONDON, Sept....
Interventional study compares VitaGraft to current transplant rejection monitoring protocolsOncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than...
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencingSALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) --...